I don’t think we’re gonna get very far asking for much in the way of specifics. (Price, hair counts, release dates, etc.) They’ve probably thought a lot about this and let out as much as they intend to right now.
I think we should just continue to press for firmer answers about the specifics of the ultimate results when it actually does go to market. I’m still half-expecting some “other shoe” to drop on the whole HM effort, and if this is the case then the sooner we find out about it the better.
– Can they give us a FIRM Y/N answer about whether ICX-TRC is creating any new terminal-growing follicles that never previously existed? (Very relevant to those who have already had major-league HTs in the past.)
– Is there ANY difference between each final ICX’d hair versus what would exist if the patient had never experienced MPB on that particular hair?
– Do we know for certain that the ICX’d hairs are cycling normally without future assistance?
– Do we know that there is absolutely no more lingering MPB susceptibility in the final ICX’d hairs than with the donor hairs used in the procedure?
Maybe this stuff seems like a bunch of foregone conclusions, but I just don’t wanna get my hopes up falsely. These medical researchers can be so “careful” about shaping their words . . . I just can’t feel safe assuming anything that they haven’t explicitly spelled-out on paper.